Back to Search Start Over

Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer.

Authors :
Maisch, Phillipp
Lunger, Lukas
Düwel, Charlotte
Schmid, Sebastian C.
Horn, Thomas
Gschwend, Jürgen E.
Sauter, Andreas
Heck, Matthias M.
Source :
Urologic Oncology. Jun2021, Vol. 39 Issue 6, p368.e11-368.e17. 1p.
Publication Year :
2021

Abstract

<bold>Background: </bold>Radical cystectomy (Cx) is the standard of care for muscle-invasive bladder cancer (BCa). In locally advanced pT4 BCa the oncologic outcome is inexplicit but Cx may be necessary for palliation.<bold>Objectives: </bold>The aim of this retrospective study was to evaluate the outcomes of Cx performed in patients with locally advanced pT4 BCa and to identify patient subgroups with improved outcome.<bold>Methods: </bold>Between 2008 and 2017, we identified 76 of 905 patients who underwent Cx for pT4 BCa at a single tertiary referral center. The physical patients' status was estimated according to the American Society of Anesthesiologists (ASA) classification. For the classification of postoperative complication rates, the Clavien-Dindo grading was used. Time-to-event variables with log-rank statistics were calculated with the use of the Kaplan-Meier method.<bold>Results: </bold>Median age was 74 years (range 42-90). Preoperatively, the physical status was estimated poor in 40 (52%) patients (ASA-score of ≥3). Overall, 19 (25%) patients had pT4b BCa, 41 (54%) patients were lymph node positive (c/pN+) and 14 (18%) patients had distant metastases (c/pM+). Within 30 and 90 days after surgery, 21% and 30% of the patients, respectively, developed severe complications (Clavien-Dindo grade ≥3). Overall, 30- and 90-day mortality rates were 9% and 11%, respectively. Moreover, 86% and 75% of patients who died within 30 and 90 days after surgery, respectively, had an ASA-score ≥3. At a median postoperative follow-up of 8 months (range 0-85), 53 (70%) patients have died. During the follow-up period, 46% of the patients died due to progressive disease, 16% died of a noncancer-specific cause, and for 8% of the patients, the reason remains unknown. Median overall survival (OS) and cancer-specific survival were 13.0 and 16.0 months, respectively. In subgroup analyses ASA-score ≥3 and hemoglobin <11.7 g/dl was significantly associated with poor OS. No statistically significant differences were detected between subgroups.<bold>Conclusion: </bold>Cx performed in patients with locally advanced pT4 BCa is associated with an increased mortality rate within 90 days postoperatively. Our study revealed that the ASA-score is a relevant and easily available tool to rate the patient´s condition and estimate postoperative outcome. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10781439
Volume :
39
Issue :
6
Database :
Academic Search Index
Journal :
Urologic Oncology
Publication Type :
Academic Journal
Accession number :
150818081
Full Text :
https://doi.org/10.1016/j.urolonc.2020.11.042